Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention CLR 125, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window.
Last mentioned: Mar 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention CLR 125, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. The 7 average consequence score is above the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Cellectar Biosciences, all published on March 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cellectar Biosciences. Shared-story counts are live from our verified record — not editorial picks.
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
Financial Results
Company reports 2025 results and provides corporate update.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Source: The Manila Times · Benzinga
Cellectar Biosciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
